Introduction {#sec1}
============

The vitamin D endocrine system is associated with many biologic responses including bone metabolism, modulation of the immune system, regulation of cell proliferation and differentiation.[@bib1] The biological active form of vitamin D is an important immunomodulatory agent which activates monocytes, stimulates cell-mediated immunity, suppresses T-lymphocytes proliferation, reduce immunoglobulin production and cytokines synthesis. Vitamin D also can suppress proinflammatory responses, and enhance innate immunity, leading to a conversion of the Th1 immune response towards the Th2 profile.[@bib2] The biological effects of vitamin D are exerted via the vitamin D receptor (VDR), a transcription factor in the nuclear receptor superfamily. VDRs promote the function of vitamin D and regulate the expression of many genes.

The VDR gene has several polymorphisms. Associations between VDR polymorphisms and susceptibility to periodontitis have been conducted in different settings and ethnic backgrounds ([Table 1](#tbl1){ref-type="table"}). The results obtained so far are conflictive. Among Chinese subjects, *Bsm*I, *Apa*I and *Taq*I genotype distributions were not significantly different between generalized aggressive periodontitis (GAgP) and healthy control (HC), but the FF genotype of *Fok*I polymorphism was overrepresented in GAgP.[@bib3] Two studies reported that the Tt genotype of *Taq*I polymorphism might be associated with the risk of developing early-onset periodontitis (EOP) among Chinese.[@bib4], [@bib5] *Taq*I polymorphism was not associated with the susceptibility to adult periodontitis among Chinese.[@bib5] Chinese subjects with the TT genotype and the T allele were more susceptible to severe CP, while *Bsm*I, *Apa*I and *Fok*I polymorphisms were not associated with risk for severe CP.[@bib6]Table 1Studies for the association of VDR genetic polymorphisms and susceptibility to periodontitis.Table 1LocusSubjectsDisease phenotypeRisksReference*Apa*I\
*Bsm*I\
*Fok*I\
*Taq*IChinese107 severe CP\
121 HC*Apa*I, *Bsm*I & *Fok*I: NS\
*Taq*I TT vs (Tt + tt) OR = 2.75\
 p = 0.02Wang et al. (2009)*Apa*I\
*Bsm*I\
*Fok*I\
*Taq*IChinese51 GAgP\
53 HC*Apa*I, *Bsm*I & *Taq*I: NS\
*Fok*I FF vs (Ff + ff) OR = 2.90\
 p = 0.04Li et al. (2008)*Apa*I\
*Bsm*I\
*Taq*ITurkish72 CP\
102 HCNSGunes et al. (2008)*Apa*I\
*Bsm*I\
*Fok*IJapanese17 severe CP\
80 not-severe CPNSNaito et al. (2007)*Bsm*I\
*Fok*I\
*Taq*IKorean93 GAgP\
143 HC*Bsm*I & *Taq*I: NS\
*Fok*I FF vs (Ff + ff) OR = 1.83\
 p = 0.03Park et al. (2006)*Taq*ICaucasian51 AgP\
57 CP\
100 HCAgP vs HC: NS\
CP vs HC TT vs (Tt + tt)\
OR = 2.7\
 p = 0.01Brett et al. (2005)*Bsm*I\
*Taq*IBrazilian69 CP\
44 HC*Bsm*I: NS\
*Taq*I (Tt + tt) vs TT OR = 2.4\
 p = 0.04de Brito et al. (2004)*Fok*I\
*Taq*IJapanese74 CP\
94 HC*Fok*I: NS\
*Taq*I TT vs Tt OR = 2.52\
 p = 0.03Tachi et al. (2003)*Taq*IJapanese\
Chinese72 AP, 94 HC\
37 EOP, 39 HCTT vs Tt OR = 2.44,  p = 0.04\
Tt vs TT OR = 5.95\
 p = 0.02Tachi et al. (2001)*Taq*IChinese24 AP, 37 EOP\
39 HCAP vs HC: NS\
EOP vs HC: Tt vs TT OR = 5.9\
 p = 0.02Sun et al. (2002)*Bsm*IJapanese42 G-EOP\
52 AP, 55 HCNSYoshihara et al. (2001)*Taq*ICaucasian49 G-EOP\
20 L-EOP\
72 HCEOP vs HC: NS\
L-EOP vs HC\
tt vs (TT + Tt) OR = 8.99\
 p = 0.001Hennig et al. (1999)[^1]

At the present time, information on the existence of VDR polymorphisms is limited to areas in the gene studied by using restriction fragment length polymorphisms (RFLP). A number of the currently known VDR polymorphisms have been depicted.[@bib7] Among them *Bsm*I*-*, *Apa*I*-*, *Taq*I*-* and *Fok*I*-*polymorphisms have been investigated in relation to periodontitis. It is very important to analyze all known VDR polymorphisms and their interrelationships, since they will interact with each other to determine VDR expression and activity.[@bib8] We were the first to examine the relationships between VDR *Bsm*I, *Apa*I, *Taq*I and *Fok*I polymorphisms/haplotypes and the risk of susceptibility to CP and AgP among Taiwanese Han individuals.

Materials and methods {#sec2}
=====================

Determination of the sample size {#sec2.1}
--------------------------------

Genetic Power Calculator was utilized to estimate power calculation.[@bib9] This sample size including 92 AgP, 385 CP and 163 HC had 80% power to detect susceptibility with a genotypic relative risk ≥1.5 at a significance level of 0.05 for a SNP with a risk allele frequency ≥0.36.[@bib10]

Study subjects {#sec2.2}
--------------

This case control study consisted of 92 AgP patients (39 females, 53 males), 385 CP patients (170 females, 215 males), and 163 ethnically matched periodontal HC (86 females, 77 males). They were recruited from patients who visited the Department of Periodontics, Kaohsiung Medical University Hospital. All subjects had at least 18 teeth when they were enrolled in the study. Exclusion criteria included systemic diseases associated with destructive periodontal disease, such as diabetes mellitus, immunosuppression, human immunodeficiency virus infection and polymorphonuclear or monocyte defects determined via the questionnaire and medical history review. Subjects who had received professional prophylaxis or had taken antibiotics in the previous 6 months, were pregnant, were lactating, or were in need of antibiotic prophylaxis before periodontal treatment were also excluded from this study. The Institutional Review Board of Kaohsiung Medical University approved the study protocol. All subjects signed informed consents. The study subjects were diagnosed as having AgP, CP, and HC on the basis of clinical examinations of probing depth (PD) and attachment loss (AL), and radiographic patterns of alveolar bone destruction. The diagnostic criteria for AgP and CP were defined in accordance with the classification agreed on at the World Workshop for Periodontics and The American Academy of Periodontology.[@bib11] Subjects who had more than eight teeth with AL ≥ 5 mm and PD ≥ 6 mm, at least three affected teeth other than first molars and incisors, and the severity of periodontal tissue destruction was not consistent with the amounts of microbial deposits were diagnosed as AgP. CP was indicated in subjects \>35 years of age, with AL ≥ 5 mm at more than one tooth, more than three sites with PD ≥ 6 mm, and lesions involving more than two teeth in each quadrant. The level of attachment loss must appear consistent with the plaque level or local contributing factors. HC was indicated by no evidence of AL ≥ 3 mm and PD \> 3 mm at more than one site. The recruited healthy controls were older than 35 years so that they could not be too young to have periodontitis. Subjects who still had the smoking habit or had quit smoking within the last 6 months before enrolling in this study were designated as current smokers. Former smokers were subjects who had quit smoking for at least 6 months.

Sample collection and DNA extraction {#sec2.3}
------------------------------------

Twenty milliliters of heparin-anticoagulated peripheral blood were collected from each study subject. Genomic DNA was extracted[@bib12] and concentration was determined by ultraviolet (UV) spectrophotometry.

Genotyping of VDR genetic polymorphisms {#sec2.4}
---------------------------------------

The rs731236 (*Taq*I), rs7975232 (*Apa*I), rs1544410 (*Bsm*I) and rs2228570 (*Fok*I) VDR genetic polymorphisms were genotyped using the polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) method. The primers and PCR conditions used to identify these four VDR SNPs are listed in [Table 2](#tbl2){ref-type="table"}. The results of each genetic polymorphism were validated by performing repeat testing and direct sequencing on 20% of the subject pool selected by random sampling. No discrepancy was found.Table 2Primers and PCR conditions used for determination of the four VDR SNPs.Table 2SNP namedbSNPPCR PrimerPCR conditionSNP 1 *Taq*I\
C/Trs731236**F** 5-CAG AGC ATG GAC AGG GAG CAA-3\
**R** 5-GCA ACT CCT CAT GGC TGA GGT CTC-3Denaturation at 95 °C for 1 min, 35 cycles at 95 °C for 1 min, 66 °C for 1 min, 72 °C for 2 min, final extension at 72 °C for 10 min\
PCR products were digested with *Taq*I (5°U/sample) at 65 °C for 4 hSNP 2 *Apa*I\
G/Trs7975232**F** 5-CAG AGC ATG GAC AGG GAG CAA-3\
**R** 5-GCA ACT CCT CAT GGC TGA GGT CTC-3Denaturation at 95 °C for 1 min, 35 cycles at 95 °C for 1 min, 66 °C for 1 min, 72 °C for 2 min, final extension at 72 °C for 10 min\
PCR products were digested with *Apa*I (10°U/sample) at 22 °C for 4 hSNP 3 *Bsm*I\
G/Ars1544410**F** 5-CAA CCA AGA CTA CAA GTA CCG CGT CAGTGA-3\
**R** 5-AAC CAG CGG GAA GAG GTC AAG GG-3Denaturation at 95 °C for 2 min, 35 cycles at 95 °C for 1 min, 63 °C for 1 min, 72 °C for 1.5 min, final extension at 72 °C for 7 min\
PCR products were digested with 1U *Bsm*I at 65 °C overnightSNP 4 *Fok*I\
T/Crs2228570**F** 5-ATG GAA ACA CCT TGC TTC TTC TCC CTC-3\
**R** 5-AGC TGG CCC TGG CAC TGA CTC TGC TCT-3Denaturation at 95 °C for 3 min, 35 cycles at 94 °C for 30 s, 60 °C for 30 s, 72 °C for 30 s, final extension at 72 °C for 5 min\
PCR products were digested with *Fok*I at 37 °C for 3 h

Statistical analysis {#sec2.5}
--------------------

Statistical analyses were performed using a JMP statistical software package (SAS Institute, Cary, NC, USA). Comparisons of descriptive statistics among the three groups were expressed as mean (±SD) and within group proportions. Differences in the demographic factors of frequency distribution and numeric data among the three groups were tested using the χ^2^-test and ANOVA test, respectively. The frequency distribution of the genotype and its allele frequencies in each group were compared by the χ^2^-test. Homozygote major allele carriers were used as the reference category. To increase statistical power for the less frequent variant, the rare homozygotes were combined with the heterozygotes assuming a dominant effect. γ^2^ was calculated to estimate linkage disequilibrium for each pair of polymorphisms. Linkage disequilibrium was measured based on calculating D′ using Haploview 4.1. The haplotype frequencies were determined by PowerMarker software V3.25. The risk association of genotypes/haplotypes/combined polymorphisms and periodontitis was computed by logistic regression analysis and expressed as an odds ratio (OR) with a 95% confidence interval (CI). Multiple testing among groups was corrected by Bonferroni method. To control the possible confounding effects, age, gender, and smoking status were used as independent variables of multiple logistic regressions for adjustment.

Results {#sec3}
=======

The same population had been recruited for our previous studies (Ho et al., 2008; Ho et al., 2010; Chou et al., 2011)[@bib13], [@bib14], [@bib15] to determine the susceptibility to periodontitis. Briefly, the demographic characteristics of the study subjects are presented in [Table 3](#tbl3){ref-type="table"}. The gender distribution was similar for these three groups. The mean age of the AgP patients was significantly lower than the CP patients and HC. The frequencies of smoking habit were significantly different between CP and HC (p = 0.001), and between AgP and HC (p = 0.042). There were more CP patients to be current smokers. The probing depth and clinical attachment level in AgP and CP were significantly higher than those in HC (p = 0.01).Table 3The demographic characteristic of studied individuals.Table 3AgP n = 92CP n = 385HC n = 163p-Value[a](#tbl3fna){ref-type="table-fn"}Gender n (%) Female39 (42.4)170 (44.2)86 (52.8)p = 0.135 Male53 (57.6)215 (55.8)77 (47.2)Age[b](#tbl3fnb){ref-type="table-fn"} (mean ± SD)37.7 ± 7.052.6 ± 7.851.1 ± 10.0p \< 0.0001Smoking[c](#tbl3fnc){ref-type="table-fn"} n (%) Non65 (70.7)277 (72.0)137 (84.0)p = 0.002 Current14 (15.2)82 (21.3)12 (7.4) Former13 (14.1)26 (6.7)14 (8.6)PD (mm) (mean ± SD)3.4 ± 0.73.5 ± 0.42.4 ± 0.2p \< 0.01CAL (mm) (mean ± SD)4.2 ± 0.34.3 ± 0.70.5 ± 0.2p \< 0.01[^2][^3][^4][^5]

The genotype frequencies of each of the VDR polymorphisms did not deviated from the Hardy--Weinberg equilibrium (p = 0.79, 0.99, 0.25, and 0.85 for rs731236, rs7975232, rs1544410, and rs2228570, respectively). In AgP patients, the genotype distribution of rs2228570 (*Fok*I) was borderline-significantly different (p = 0.007) from the HC ([Table 4](#tbl4){ref-type="table"}). When the minor allele frequency of rs2228570 was compared between AgP and HC, the frequency of f allele was significantly lower in AgP (adjusted OR = 0.57, 95% CI = 0.39--0.82, p = 0.003). The frequencies of genotype and minor allele of the other SNPs were not significantly different between AgP and HC. In CP patients, logistic regression analysis showed the genotype distributions and the minor allele frequencies of the investigated four SNPs were not significantly different from the HC ([Table 4](#tbl4){ref-type="table"}).Table 4Genotype distribution of VDR SNPs in periodontitis patients and healthy controls.Table 4GenotypeHC n = 163AgP n = 92CP n = 385n (%)n (%)Adjusted OR[a](#tbl4fna){ref-type="table-fn"}95% CIp-Value[b](#tbl4fnb){ref-type="table-fn"}n (%)Adjusted OR[a](#tbl4fna){ref-type="table-fn"}95% CIp-Value[b](#tbl4fnb){ref-type="table-fn"}rs731236 (*Taq*I)0.110.05 TT152 (93.3)81 (88.0)1Reference352 (91.4)1Reference Tt9 (5.5)11 (12.0)2.290.91--5.760.0733 (8.6)1.580.74--3.390.23 tt2 (1.2)0 (0)00.300 (0)00.03 MAF (%)4.06.01.530.66--3.450.314.30.930.47--1.750.82 Tt/tt[c](#tbl4fnc){ref-type="table-fn"}11 (6.8)11 (12.0)0.860.24--3.050.8233 (8.6)1.430.72--3.070.33rs7975232 (*Apa*I)0.480.28 aa80 (49.1)41 (44.6)1Reference177 (46.0)1Reference Aa72 (44.2)41 (44.6)1.110.65--1.900.70165 (42.9)1.040.71--1.520.86 AA11 (6.7)10 (10.8)1.770.70--4.520.2343 (11.1)1.770.87--3.600.11 MAF (%)28.833.21.220.83--1.800.3132.61.190.90--1.590.22 Aa/AA[c](#tbl4fnc){ref-type="table-fn"}83 (50.9)51 (55.4)1.210.40--1.690.60208 (54.0)1.130.77--1.660.52rs1544410 (*Bsm*I)0.070.04 bb115 (70.5)75 (81.5)1Reference308 (80.0)1Reference Bb43 (26.4)13 (14.1)0.460.23--0.920.0372 (18.7)0.630.40--0.970.03 BB5 (3.1)4 (4.4)1.230.32--4.720.775 (1.3)0.370.11--1.310.11 MAF (%)16.311.40.660.38--1.130.1410.60.610.42--0.900.01 Bb/BB[c](#tbl4fnc){ref-type="table-fn"}48 (29.5)17 (18.5)0.330.13--0.790.0277 (20.0)0.580.38--0.900.01rs2228570 (*Fok*I)0.0070.23 FF43 (26.4)42 (45.6)1Reference104 (27.0)1Reference Ff76 (46.6)33 (35.9)0.440.25--0.800.007202 (52.5)1.100.71--1.710.68 ff44 (27.0)17 (18.5)0.400.20--0.800.00979 (20.5)0.740.44--1.240.25 MAF (%)50.336.40.570.39--0.820.00346.80.870.67--1.120.28 Ff/ff[c](#tbl4fnc){ref-type="table-fn"}120 (73.6)50 (54.4)0.480.23--0.990.048281 (73.0)0.950.62--1.450.82[^6][^7][^8][^9]

The linkage disequilibrium coefficient (r^2^) and D′ value was measured to determine the linkage disequilibrium between these four VDR SNPs. The plot shown in [Fig. 1](#fig1){ref-type="fig"} identified significant linkage disequilibrium between rs731236 and rs7975232, and between rs731236 and rs1544410. The linkage disequilibrium between rs2228570 and the other three SNPs was weak. VDR haplotype comprising rs731236 and rs7975232 did not demonstrate greater effect on risk for AgP and CP than the individual genotype (data not shown).Figure 1Linkage disequilibrium plot of four SNPs in the VDR gene. The number in the square is the D′ value.Figure 1

Fifteen different combined polymorphisms were identified after analyzing combinations of the genotype frequencies for the 4 VDR polymorphisms. The AgP had 12-, CP had 13- and HC had 10 combined polymorphisms. We selected the combined polymorphisms of higher frequencies (Tabf, TabF, TAbF, and TAbf, ranging from 33% to 8%) for further analysis ([Table 5](#tbl5){ref-type="table"}). These four combined polymorphisms were not associated with risk for AgP. The Tabf combined polymorphism had a positive correlation with the risk for CP (adjusted OR = 1.69, 95% CI = 1.28--2.27, p = 0.0003). The TabF and TAbf combined polymorphisms had a negative correlation with the risk for CP (adjusted OR = 0.50, 95% CI = 0.33--0.75, p = 0.001 and adjusted OR = 0.36, 95% CI = 0.20--0.65, p = 0.001, respectively). The TAbF combined polymorphism was not associated with the risk for CP.Table 5Association between the combined VDR polymorphisms and risk for periodontitis.Table 5Combined polymorphism[a](#tbl5fna){ref-type="table-fn"}HC n = 163AgP n = 92CP n = 385n (%)n (%)Adjusted OR[b](#tbl5fnb){ref-type="table-fn"}95% CIp-Value[c](#tbl5fnc){ref-type="table-fn"}n (%)Adjusted OR[b](#tbl5fnb){ref-type="table-fn"}95% CIp-Value[c](#tbl5fnc){ref-type="table-fn"}Tabf −241 (73.9)139 (75.5)1Reference482 (62.6)1Reference +85 (26.1)45 (24.5)0.920.60--1.390.69288 (37.4)1.691.28--2.270.0003 No copy94 (57.7)52 (56.5)1Reference135 (35.1)1Reference 1 or 2 copies69 (42.3)40 (43.5)1.220.63--2.370.56250 (64.9)2.581.76--3.80\<0.0001TabF −198 (60.7)111 (60.3)1Reference564 (73.3)1Reference +128 (39.3)73 (39.7)1.170.60--2.290.65206 (26.7)0.500.33--0.750.001 No copy51 (31.3)40 (43.5)1Reference214 (55.6)1Reference 1 or 2 copies112 (68.7)52 (56.5)0.650.33--6.50.21171 (44.4)0.360.24--0.53\<0.0001TAbF −309 (94.8)147 (79.9)1Reference642 (83.4)1Reference +17 (5.21)37 (20.1)14.971.69--348.10.03128 (16.6)4.690.88--86.70.144 No copy147 (90.2)61 (66.3)1Reference263 (68.3)1Reference 1 or 2 copies16 (9.8)31 (33.7)7.193.21--7.20\<0.0001122 (31.7)4.422.57--8.07\<0.0001TAbf −283 (86.8)177 (96.2)1Reference712 (92.5)1Reference +43 (13.2)7 (3.8)0.080.004--0.080.01958 (7.5)0.360.20--0.650.001 No copy123 (75.5)85 (92.4)1Reference335 (87.0)1Reference 1 or 2 copies40 (24.5)7 (7.6)0.170.05--0.480.00250 (13.0)0.450.28--0.730.001[^10][^11][^12][^13]

[Table 5](#tbl5){ref-type="table"} also shows the individuals with one or two copies of TAbF could have increased risk for AgP (adjusted OR = 7.19, 95% CI = 3.21--7.20, p \< 0.0001); individuals with one or two copies of TAbf could have reduced risk for AgP (adjusted OR = 0.17, 95% CI = 0.05--0.48, p = 0.002). Subjects with one or two copies of Tabf (adjusted OR = 2.58, 95% CI = 1.76--3.80, p \< 0.0001), or TAbF (adjusted OR = 4.42, 95% CI = 2.57--8.07, p \< 0.0001) could have increased risk for the development of CP. Individuals with one or two copies of TabF (adjusted OR = 0.36, 95% CI = 0.24--0.53, p \< 0.0001), or TAbf (adjusted OR = 0.45, 95% CI = 0.28--0.73, p = 0.001) could have a decreased risk for the susceptibility to CP.

Discussion {#sec4}
==========

Our results revealed that: (1) the individual polymorphism was not associated with susceptibility to AgP and CP; (2) the f allele of rs2228570 was associated with reduced risk for developing AgP. The studied individual VDR polymorphism was not related to risk for CP. The results differed from the report by Deng et al.[@bib16] which showed CP had a significantly lower frequency of bb genotype of *Bsm*I, higher frequency of AA genotype of *Apa*I, and TT genotype of *Taq*I; but no significant difference in any genotype of *Fok*I. We showed no association of VDR gene polymorphisms with AgP. It was in consistent with the results of Deng et al.[@bib16] Another meta-analysis indicated that mutant allele t of *Taq*I locus may be a protective factor for CP, but not for AgP; the mutant allele F of the *Fok*I locus appeared to be a risk factor for AgP rather than CP; *Bsm*I and *Apa*I polymorphisms were not associated with the susceptibility to periodontitis.[@bib17] We also found the f allele of *Fok*I polymorphism was associated with reduced risk for AgP, but not for CP. In contrast to this recent meta-analysis, our study indicated that *Taq*I was not related to the susceptibility to periodontitis. The allelic distribution of *Taq*I polymorphism found in the present study was comparable to that reported in the published study for Chinese.[@bib5] However, *Taq*I-RFLP was not associated with the susceptibility to AgP and CP in our sample. This differed from the previous association studies that showed *Taq*I polymorphism was linked to EOP and CP susceptibility ([Table 1](#tbl1){ref-type="table"}). The carriage rate of VDR *Taq*I t allele was quite different between different ethnic populations. The t allele was not associated with susceptibility to periodontitis in our subjects; however, this might be relative to the very low carriage rate of the t allele in Taiwanese.

The *Fok*I SNP is a functional polymorphism in the start condon at the 5′ promotor region of the VDR gene. The stronger interaction of the F allele with transcription factor can translate stronger signaling messages for bone resorption and inflammation. These findings might explain why the FF genotype and F allele had positive associations with the risk for the susceptibility to periodontitis. To our knowledge, the biological effects of *Fok*I-polymorphism on periodontal tissue remain unknown.

In a study about *Bsm*I SNP effect on VDR level showed the B allele was associated with higher VDR levels.[@bib18] In contrast, other studies reported *Bsm*I SNP did not affect either the VDR mRNA level[@bib19]) or VDR function.[@bib20] The *Taq*I genetic variant effects on the mRNA stability have been evaluated. So far, the results are conflictive. Individuals with tt genotype had significantly lower levels of both VDR mRNA expression and protein and stronger inflammatory responses. The b, a, and T alleles and baT haplotype were associated with lower VDR mRNA levels.[@bib21] The B, t and F allele of *Bsm*I-, *Taq*I- and *Fok*I-polymorphisms were highly responsive compared to b, T, and f alleles. VDR BB, tt, and FF genotypes and composite genotype BBAAtt, and haplotype BAt are associated with the increased expression of VDR.[@bib22]

Previous studies reported that the haplotype or combined VDR polymorphisms might affect VDR expression[@bib18], [@bib21], [@bib22] consequently might predict periodontitis. In Caucasians, the rs731236 is in strong linkage disequilibrium with the rs7975232 and rs1544410, while rs2228570 site appears to be an independent marker. Our subjects demonstrated the same result of linkage disequilibrium analysis. The VDR haplotypes comprising rs731236 and rs7975232 did not associate with risk for AgP and CP, while the combined polymorphisms did demonstrate greater effect on risk for CP than the individual genotypes. Carriage of Tabf was related to the increased risk of CP. TabF and TAbf were associated with decreased risk of CP. In conclusion, the present study used a candidate gene approach and replicated previous studies in different populations ([Table 1](#tbl1){ref-type="table"}). A future well-designed genetic study with large and sufficiently powered case-control samples to identify genetic variance in periodontitis is necessary.[@bib7], [@bib23] Nevertheless, our present investigation supports the potential effects of VDR polymorphisms on CP and AgP in a Taiwan population; however, the pattern of association was different between the two diseases. The f-allele of rs2228570 might be the genetic protective factor against the development of AgP.
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[^1]: AgP: aggressive periodontitis; AP: adult periodontitis; CP: chronic periodontitis; EOP: early-onset periodontitis; L-EOP: localized early-onset periodontitis; G-EOP: generalized early-onset periodontitis; NS: no association.

[^2]: AgP: aggressive periodontitis; CP: chronic periodontitis; HC: healthy controls; PD: probing depth; CAL: clinical attachment level.

[^3]: Comparisons performed by χ^2^-test or ANOVA.

[^4]: Age: p \< 0.0001 for AgP vs HC; not significant for CP vs HC.

[^5]: Smoking status: p = 0.042 for AgP vs HC; p = 0.001 for CP vs HC.

[^6]: AgP: aggressive periodontitis; CP: chronic periodontitis; HC: healthy controls; MAF: minimal allelic frequency; OR: odds ratio; CI: confidence interval.

[^7]: Adjusted for gender, age and smoking status for logistic regression analysis.

[^8]: p \< 0.006 was accepted as significant for multiple testing corrected by Bonferroni method.

[^9]: t carrier, A carrier, B carrier or f carrier versus each reference.

[^10]: AgP: aggressive periodontitis; CP: chronic periodontitis; HC: healthy controls; OR: odds ratio; CI: confidence interval.

[^11]: The order of SNPs in the combined polymorphism is *Taq*I-, *Apa*I-, *Bsm*I-, and *Fok*I-polymorphism.

[^12]: Adjusted for gender, age and smoking status for logistic regression analysis.

[^13]: p \< 0.0125 was accepted as significant for multiple testing corrected by Bonferroni method.
